David H. Munn

Active 1987–2025

Also published as
David, H. Munn
131
Papers
38,022
Citations
97
h-index
130
i10-index

Citations

Citations per year for David H. Munn1989: 3 citations1990: 5 citations1991: 4 citations1992: 7 citations1993: 2 citations1994: 3 citations1995: 8 citations1996: 13 citations1997: 15 citations1998: 17 citations1999: 31 citations2000: 49 citations2001: 61 citations2002: 122 citations2003: 169 citations2004: 241 citations2005: 323 citations2006: 379 citations2007: 455 citations2008: 415 citations2009: 410 citations2010: 395 citations2011: 383 citations2012: 466 citations2013: 389 citations2014: 489 citations2015: 682 citations2016: 559 citations2017: 715 citations2018: 650 citations2019: 1,495 citations2020: 1,702 citations2021: 1,853 citations2022: 1,235 citations2023: 940 citations2024: 1,333 citations2025: 688 citations2026: 17 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,088 citing papers, 27.6% of this breakdownChina: 2,634 citing papers, 17.8% of this breakdownGermany: 760 citing papers, 5.1% of this breakdownUnited Kingdom: 692 citing papers, 4.7% of this breakdownItaly: 651 citing papers, 4.4% of this breakdownFrance: 505 citing papers, 3.4% of this breakdownJapan: 477 citing papers, 3.2% of this breakdownAustralia: 444 citing papers, 3% of this breakdownNetherlands: 345 citing papers, 2.3% of this breakdownCanada: 337 citing papers, 2.3% of this breakdownSouth Korea: 266 citing papers, 1.8% of this breakdownSwitzerland: 243 citing papers, 1.7% of this breakdown
0%27.6%Other 22.7%

Fields

  • Immunology and Microbiology30.4%
  • Medicine30.3%
  • Biochemistry, Genetics and Molecular Biology22.7%
  • Neuroscience11.9%
  • Engineering1.8%
  • Agricultural and Biological Sciences0.8%
  • Other2.1%

Topics

  • Immune Cell Function and Interaction7.8%
  • Cancer Immunotherapy and Biomarkers6.2%
  • Immune cells in cancer5.6%
  • Immunotherapy and Immune Responses5.3%
  • Tryptophan and brain disorders5%
  • Gut microbiota and health4.4%
  • Other65.7%

Coauthors

All papers

Open in search
  1. Activation of Gpr109a, Receptor for Niacin and the Commensal Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis

    Authors: , , , , , , , , , , , , - Immunity 2014 cited by 2,275

  2. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

    Authors: , - Trends in Immunology 2016 cited by 1,024

  3. Ido expression by dendritic cells: tolerance and tryptophan catabolism

    Authors: , - Nature reviews. Immunology 2004 cited by 2,315

  4. Indoleamine 2,3 dioxygenase and metabolic control of immune responses

    Authors: , - Trends in Immunology 2012 cited by 1,007

  5. GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction in Response to Indoleamine 2,3-Dioxygenase

    Authors: , , , , , , - Immunity 2005 cited by 1,245

  6. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Immunity 2020 cited by 218

  7. Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism

    Authors: , , , , , - The Journal of Experimental Medicine 1999 cited by 1,617

  8. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2022 cited by 155

  9. Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment

    Authors: , , , , , , , , , , - Cancer Cell 2023 cited by 119

  10. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

    Authors: , , , , , , , , , , - Blood 2011 cited by 679

  11. Immune suppressive mechanisms in the tumor microenvironment

    Authors: , - Current Opinion in Immunology 2015 cited by 524

  12. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

    Authors: , , , , , , , - Cancer Research 2016 cited by 325

  13. Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism

    Authors: , , , , , , , - Science 1998 cited by 2,592

  14. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

    Authors: , , , , , , , - Cell Reports 2015 cited by 488

  15. Apoptotic cell–induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Immunology 2018 cited by 201

  16. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

    Authors: , , , , - The Journal of Experimental Medicine 2013 cited by 636

  17. GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment

    Authors: , , , , , , , , , , , , , , , , , , - Science Immunology 2019 cited by 186

  18. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression

    Authors: , , , , , , , , , , , , , , , , , , - Nature Communications 2019 cited by 158

  19. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint

    Authors: , , , , , , , , , , , , , , - Nature Communications 2020 cited by 185

  20. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 110

  21. The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation

    Authors: , , , , - The Journal of Immunology 2008 cited by 454

  22. Indoleamine 2,3-dioxygenase and tumor-induced tolerance

    Authors: , - Journal of Clinical Investigation 2007 cited by 1,064

  23. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

    Authors: , , , , , , , - OncoImmunology 2012 cited by 377

  24. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells

    Authors: , , , , , , , , , - American Journal of Physiology-Gastrointestinal and Liver Physiology 2012 cited by 277